STEMdiff™ T Cell Kit

For expansion and differentiation of hPSCs to T cells
STEMdiff™ T Cell Kit

For expansion and differentiation of hPSCs to T cells

1 Kit
Catalog # 100-0194
1,754 USD

INDIVIDUAL COMPONENTS

STEMdiff™ Hematopoietic - EB Basal Medium

305 USD
Catalog # 100-0171
120 mL

Medium for the generation of embryoid bodies for downstream lymphoid differentiation

STEMdiff™ Hematopoietic - EB Supplement A

202 USD
Catalog # 100-0172
265 µL

Supplement for mesoderm specification with downstream lymphoid potential

STEMdiff™ Hematopoietic - EB Supplement B

353 USD
Catalog # 100-0173
7 mL

Supplement for hematopoietic differentiation optimized for lymphoid potential

Required Products
  1. 37μm Reversible Strainers|27215,27250
    Reversible Strainers

    Reversible strainer for filtration of single cells and isolation of cellular aggregates, including embryoid bodies and spheroids

  2. Y-27632 (Dihydrochloride)
    Y-27632

    RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2

  3. AggreWell™400 24-well plate|34411
    AggreWell™400

    Microwell culture plates for easy and reproducible production of embryoid bodies and spheroids

  4. EasySep™ Human CD34 Positive Selection Kit II|17856
    EasySep™ Human CD34 Positive Selection Kit II

    Immunomagnetic positive selection kit

Overview

STEMdiff™ T Cell Kit includes serum-free media and supplements for the feeder-free differentiation of human pluripotent stem cells (hPSCs) to T cells.

STEMdiff™ Hematopoietic - EB reagents are animal component-free and optimized for lymphoid differentiation potential. Using these reagents, CD34⁺ hematopoietic progenitor cells are first generated from hPSCs; these can then be differentiated to T cells using the StemSpan™ components.
Advantages
⦁ Serum-free and feeder-free formulation
⦁ Uniform generation of embryoid bodies
⦁ Robust generation of CD4+CD8+ double-positive T cells across multiple ES and iPS cell lines
Components
  • STEMdiff™ Hematopoietic - EB Basal Medium, 120 mL (Catalog #100-0171)
  • STEMdiff™ Hematopoietic - EB Supplement A, 265 μL (Catalog #100-0172)
  • STEMdiff™ Hematopoietic - EB Supplement B, 7 mL (Catalog #100-0173)
  • StemSpan™ SFEM II, 2 x 100 mL (Catalog #09605)
  • StemSpan™ Lymphoid Progenitor Expansion Supplement (10X), 5 mL (Catalog #09915)
  • StemSpan™ Lymphoid Differentiation Coating Material (100X), 2 x 0.25 mL (Catalog #09925)
  • StemSpan™ T Cell Progenitor Maturation Supplement (10X), 12.5 mL (Catalog #09930)
Subtype
Specialized Media
Cell Type
Hematopoietic Cells, PSC-Derived, Pluripotent Stem Cells, T Cells, T Cells, CD8+
Species
Human
Application
Cell Culture, Differentiation, Expansion
Brand
STEMdiff
Area of Interest
Cancer, Disease Modeling, Immunology, Stem Cell Biology
Formulation
Serum-Free

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
STEMdiff™ Hematopoietic - EB Basal Medium
Catalog #
100-0171
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
STEMdiff™ Hematopoietic - EB Supplement A
Catalog #
100-0172
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
STEMdiff™ Hematopoietic - EB Supplement B
Catalog #
100-0173
Lot #
All
Language
English
Document Type
Manual
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet 7
Product Name
STEMdiff™ T Cell Kit
Catalog #
100-0194
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
STEMdiff™ Hematopoietic - EB Basal Medium
Catalog #
100-0171
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
STEMdiff™ Hematopoietic - EB Supplement A
Catalog #
100-0172
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
STEMdiff™ Hematopoietic - EB Supplement B
Catalog #
100-0173
Lot #
All
Language
English

Educational Materials (7)

Brochure
Hematopoietic Stem and Progenitor Cells - Products for Your Research
Brochure
Tools For Your Immunology Research
Technical Bulletin
Generation of T Cells from Human Pluripotent Stem Cells Using STEMdiff™ and StemSpan™ Media and Supplements
Wallchart
Derivation and Applications of Human Pluripotent Stem Cells
Webinar
Accelerating T Cell Therapy Research
Webinar
Online Immunology Journal Club: Expanding the Therapeutic Tool Kit for CAR T Cells
47:14
Online Immunology Journal Club: Expanding the Therapeutic Tool Kit for CAR T Cells
Webinar
ISSCR Innovation Showcase: Differentiating Immune Cells from Human Pluripotent Stem Cells in Feeder- and Serum-Free Cultures
29:54
ISSCR Innovation Showcase: Differentiating Immune Cells from Human Pluripotent Stem Cells in Feeder- and Serum-Free Cultures

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Figure 1. STEMdiff™ Hematopoietic - EB Progenitor Differentiation Protocol

hPSCs are harvested and dissociated into a single-cell suspension prior to seeding into AggreWell™ plates in EB Formation Medium (EB Medium A + 10 μM Y-27632) to form 600-cell aggregates. After 3 days of mesoderm formation, the medium is changed to EB Medium B to induce hematopoietic lineage differentiation. On day 5, EBs are transferred onto non-tissue culture-treated plates. After a total of 12 days, EBs are harvested and dissociated, and CD34+ cells are then enriched by EasySep™ positive selection.

Figure 2. hPSCs Differentiate to CD34+ Hematopoietic Progenitor Cells After 12 Days of Culture

Human ES and iPS cells were induced to differentiate to CD34+ cells using the 12-day protocol shown in Figure 1. At the end of the culture period, cells were harvested, dissociated into a single-cell suspension, and analyzed by flow cytometry for CD34 and CD144 expression. Dead cells were excluded by light-scatter profile and DRAQ7™ staining. Representative flow cytometry plot for (A) ES (H1) cell-derived and (B) iPS (STiPS-F016) cell-derived cells analyzed on day 12 are shown. (C) The average frequency of viable CD34+ cells on day 12 (before CD34+ cell isolation) for two ES cell lines (H1 and H9) and three iPS cell lines (WLS-1C, STiPS-M001, and STiPS-F016) ranged between 31% and 51%. The average yield of CD34+ cells produced per well of a 6-well AggreWell™400 plate ranged between 4.0 x 105 and 6.7 x 105. Data are shown as mean ± SEM (n = 9 - 35). Results are representative of populations prior to magnetic cell separation.

Figure 3. T Cell Generation Protocol

hPSC-derived CD34+ cells are seeded in StemSpan™ Lymphoid Progenitor Expansion Medium on plates coated with StemSpan™ Lymphoid Differentiation Coating Material. On day 14, cells at the lymphoid progenitor stage are harvested and reseeded in StemSpan™ T Cell Progenitor Maturation Medium onto coated plates for further differentiation to CD4+CD8+ DP T cells. The DP T cells are harvested after 28 days.

Figure 4. hPSC-Derived CD34+ Cells Differentiate to CD5+CD7+ Lymphoid Progenitor Cells Over 14 Days of Culture

hPSC-derived CD34+ cells were cultured for 14 days in StemSpan™ SFEM II + StemSpan™ Lymphoid Progenitor Expansion Supplement on plates coated with StemSpan™ Lymphoid Differentiation Coating Material (Figure 3). Cells were harvested and analyzed for CD7 and CD5 expression by flow cytometry. Representative flow cytometry plots for (A) ES (H1) cell-derived and (B) iPS (STiPS-F016) cell-derived cells are shown. (C) The average frequency of viable CD7+CD5+ lymphoid progenitor cells on day 14 ranged between 38% and 54%, and the average yield of lymphoid progenitor cells produced per input hPSC-derived CD34+ cell was between 12 and 40. Data are shown as mean ± SEM (n = 8 - 32).

Figure 5. CD4+CD8+ DP T Cells Can Be Generated from Human hPSC-Derived CD34+ Cells After 28 Days of Culture

DP T cells were differentiated from hPSC-derived CD34+ cells as described (Figure 3). Cells were harvested and analyzed for expression of CD3, CD4, CD8, and TCRαβ by flow cytometry. Representative flow cytometry plots are shown for (A,B) ES (H1) cell-derived and (C,D) iPS (STiPS-F016) cell-derived cells. (E) The average frequency of viable CD4+CD8+ DP T cells on day 28 ranged between 23% and 58%, and the average yield of DP T cells produced per input hPSC-derived CD34+ cell was between 12 and 108. (F) The average frequency of CD3+TCRαβ+ expressed on DP T cells ranged between 11% and 38%. Data are shown as mean ± SEM (n = 6 - 17).

Figure 6. Optional CD8+ SP T Cell Maturation Protocol

DP T cells are seeded in CD8+ SP T Cell Maturation Medium supplemented with ImmunoCult™ T Cell Activator on plates coated with StemSpan™ Lymphoid Differentiation Coating Material. CD8+ SP T cells can be harvested after 7 days.

Figure 7. hPSC-Derived CD4+CD8+ DP T Cells Are Able to Mature to CD8+ SP T Cells

hPSC-derived CD34+ cells were first differentiated to DP T cells during 28 days of culture (Figure 3), and were then matured to CD8+ SP T cells using an additional 7-day maturation protocol (Figure 6). Cells were harvested and analyzed by flow cytometry for expression of (A,D) CD3 and TCRαβ, (B,E) CD4 and CD8 (gated on CD3+TCRαβ+), and (C,F) CD8α and CD8β (gated on CD8+ SP). Representative results for (A,B,C) ES (H1) cell-derived and (D,E,F) iPS (STiPS-F016) cell-derived cells are shown. (G) The average frequency of CD3+TCRαβ+CD4-CD8+ (CD8+SP) T cells was between 3% and 28%. Data are shown as mean ± SEM (n = 2 - 9).

Figure 8. hPSC-Derived CD8+ SP T Cells Can Be Induced to Express Activation Markers CD25 and CD69, Degranulate, and Produce IFN-γ

hPSC-derived CD34+ cells were first differentiated to DP T cells during 28 days of culture and then matured to CD8+ SP T cells using an additional 7-day maturation protocol (Figures 3 and 6). CD8+ SP T cells were sorted using fluorescence-activated cell sorting and cultured for 7 days in ImmunoCult™-XF T Cell Expansion Medium supplemented with IL-2 and stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator. Cells were harvested and analyzed by flow cytometry for expression of (A,D) CD25 and CD69. For assessment of degranulation and cytokine production, at 4 hours prior to harvest, some cells were also stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin. After one hour, monensin and brefeldin A were added to each well to inhibit protein transport. Control (unstimulated; black histogram) and PMA + ionomycin-stimulated cells (orange histogram) were additionally analyzed by flow cytometry for surface expression of (C,F) CD107a (lysosomal-associated membrane protein 1 or LAMP-1) indicating degranulation and intracellular expression of (B,E) IFN-γ (gated on CD8+ SP). Representative results for (A,B,C) ES (H1) cell-derived and (D,E,F) iPS (STiPS-F016) cell-derived cells are shown.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.